Traditional Chinese medicine compound essential oil and application thereof in preparation of products for preventing and treating hyperlipidemia

The compound essential oil, composed of Morinda officinalis, Coptis chinensis, and Aucklandia lappa essential oils, solves the problem of the limited mechanism of single essential oils, achieving comprehensive regulation of hyperlipidemia, significantly reducing weight and blood lipid levels, improving liver lipid metabolism, and has a safe and environmentally friendly therapeutic effect.

CN121287803AActive Publication Date: 2026-01-09THE FIRST AFFILIATED HOSPITAL OF HENAN UNIV OF TCM
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202511396819.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-09-28
Publication Date
2026-01-09
Estimated Expiration
2045-09-28

AI Technical Summary

Technical Problem

Existing Chinese herbal essential oils have a single mechanism of action in treating hyperlipidemia, lacking a comprehensive effect on regulating lipid metabolism, and drug treatment may bring toxic side effects.

Method used

This invention provides a compound essential oil of traditional Chinese medicine composed of Morinda officinalis, Coptis chinensis and Aucklandia lappa essential oils. The oil is extracted by supercritical carbon dioxide extraction, and the purity of the essential oil is maintained at over 99%. It is used to prepare external dosage forms for aromatherapy, with the addition of medically acceptable excipients, for the prevention and treatment of hyperlipidemia.

Benefits of technology

It significantly reduces body weight and serum and liver levels of triglycerides, cholesterol, and LDL in a hyperlipidemic mouse model, increases HDL levels, regulates lipid metabolism, inhibits hepatic steatosis, and achieves therapeutic effects on hyperlipidemia by upregulating genes related to lipid oxidation and decomposition.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121287803A_ABST
    Figure CN121287803A_ABST
Patent Text Reader

Abstract

The invention provides compound essential oil of bastardwood and application of the compound essential oil in preparation of products for preventing and treating hyperlipidemia, and relates to the technical field of traditional Chinese medicine essential oil. The traditional Chinese medicine compound essential oil is prepared from radix morindae officinalis essential oil, rhizoma coptidis essential oil and radix aucklandiae essential oil. The traditional Chinese medicine compound essential oil can significantly reduce the weight gain trend of a hyperlipidemia mouse model, reduce the weight of the mouse, effectively reduce the triglyceride, cholesterol and LDL level in serum and liver of the hyperlipidemia mouse model, improve the HDL level, significantly improve the hyperlipidemia symptom of the model mouse, and achieve the purpose of regulating lipid metabolism; meanwhile, liver fatty degeneration can be inhibited, the diameter of fat cells is reduced, and the traditional Chinese medicine compound essential oil has huge application potential in treatment or prevention of hyperlipidemia.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of traditional Chinese medicine essential oil technology, specifically to a compound essential oil of traditional Chinese medicine and its application in the preparation of products for the prevention and treatment of hyperlipidemia. Background Technology

[0002] Hyperlipidemia is characterized by elevated cholesterol and free fatty acid levels, elevated low-density lipoprotein cholesterol (LDL) levels, and decreased high-density lipoprotein cholesterol (HDL) levels. Hyperlipidemia is closely associated with a variety of health problems, including the combined effects of diabetes, obesity, and hypertension, known as metabolic syndrome, which seriously endangers human health. In particular, when accompanied by overweight and obesity, patients experience excessive accumulation of serum triglycerides (TG), mild or severe liver inflammation, and an increased risk of coronary artery disease, hypertension, respiratory diseases, and obstructive sleep apnea, while also imposing a significant economic burden on society. A cross-sectional study based on physical examination data from 15.8 million adults in 2019 showed that the prevalence of overweight and obesity in my country was 34.8% and 14.1%, respectively. Overweight / obesity in China generally shows a higher prevalence in men than women, and a higher prevalence in the north than in the south. Therefore, controlling hyperlipidemia symptoms in obese patients or those with metabolic syndrome is urgent.

[0003] Currently, relevant guidelines both domestically and internationally recommend lifestyle interventions as the first-line treatment for hyperlipidemia, which involves improving the condition through diet and exercise. This is followed by drug treatment for hyperlipidemia. However, this approach may lead to drug interactions and even toxic side effects, affecting the final treatment outcome.

[0004] Herbal essential oils are volatile oily liquids extracted from Chinese medicinal herbs. They can be extracted from the roots, stems, flowers, leaves, seeds, and fruits of these herbs. The chemical composition of essential oils extracted from different parts of the same herb varies, resulting in different functions and effects. In modern society, with significantly improved living standards, people not only want to meet various needs but also desire safer, more environmentally friendly, and greener products. Herbal essential oils, derived directly from nature, have complex compositions, mainly including terpenoids, aromatic compounds, aliphatic compounds, and nitrogen- and sulfur-containing compounds. Compared to synthetically produced chemicals, they are less toxic and safer. They exhibit good biological activity in areas such as anti-tumor, antiviral, sedative, antioxidant, lipid metabolism regulation, and immune regulation, showing broad application prospects in the future.

[0005] Currently, many single-herb essential oils have been proven to combat hyperlipidemia, such as Magnolia officinalis essential oil, Angelica sinensis essential oil, and Salvia miltiorrhiza essential oil. However, evidence suggests that these single-herb essential oils have weaknesses, such as a relatively singular mechanism of action. In contrast, traditional Chinese medicine compound formulas have advantages such as rational interaction ratios, targeted complementary benefits, and comprehensive effects. Therefore, it is necessary to continuously conduct research on the formulation and optimization of traditional Chinese medicine compound formulas to find new compound formulas that are highly targeted at hyperlipidemia and can regulate lipid metabolism, and it is also essential to develop their applications. Summary of the Invention

[0006] (a) Technical problems to be solved

[0007] To address the shortcomings of existing technologies, this invention provides a traditional Chinese medicine compound essential oil and its application in the preparation of products for the prevention and treatment of hyperlipidemia.

[0008] (II) Technical Solution

[0009] To achieve the above objectives, the present invention provides the following technical solution:

[0010] In a first aspect, the present invention provides a traditional Chinese medicine compound essential oil, wherein the traditional Chinese medicine compound essential oil is composed of the following volume parts of traditional Chinese medicine plant essential oils: 0.1-2 parts of Morinda officinalis essential oil, 0.5-3 parts of Coptis chinensis essential oil, and 0.5-3 parts of Aucklandia lappa essential oil.

[0011] Furthermore, the herbal compound essential oil is composed of the following volume parts of herbal plant essential oils: 0.3-1.2 parts of Morinda officinalis essential oil, 0.8-2 parts of Coptis chinensis essential oil, and 0.8-2 parts of Aucklandia lappa essential oil.

[0012] Furthermore, the herbal compound essential oil is composed of the following volume parts of herbal plant essential oils: 0.6 parts of Morinda officinalis essential oil, 1 part of Coptis chinensis essential oil, and 1 part of Aucklandia lappa essential oil.

[0013] Furthermore, Morinda officinalis essential oil, Coptis chinensis essential oil, and Costus root essential oil are obtained by extracting Morinda officinalis, Coptis chinensis, and Costus root using supercritical carbon dioxide extraction, respectively, with the purity of the essential oils maintained at over 99%.

[0014] Furthermore, Morinda officinalis essential oil, Coptis chinensis essential oil, and Costus root essential oil can also be purchased commercially.

[0015] Secondly, the present invention also provides the application of the above-mentioned compound essential oil of traditional Chinese medicine in the preparation of products for the prevention and / or improvement and / or treatment of hyperlipidemia. The product is an aromatherapy product, specifically made by weighing Morinda officinalis essential oil, Coptis chinensis essential oil and Aucklandia lappa essential oil according to the above-mentioned volume proportions, mixing them evenly, adding medically acceptable excipients, and preparing an external dosage form for aromatherapy.

[0016] Furthermore, in the product for preventing and / or improving and / or treating hyperlipidemia, the effective content of the herbal relapse essential oil is more than 20%.

[0017] Morinda officinalis root (Ba Ji Tian): The dried root of Morinda officinalis How, a plant in the Rubiaceae family. It has a sweet and pungent taste, is slightly warm in nature, and enters the kidney and liver meridians. It tonifies kidney yang, strengthens tendons and bones, and dispels wind and dampness. It is commonly used for impotence, seminal emission, infertility due to cold uterus, irregular menstruation, lower abdominal pain due to cold, rheumatic pain, and weakness of tendons and bones. Morinda officinalis contains anthraquinones, iridoids, sugars, lignins, and volatile oils, exhibiting pharmacological effects such as antioxidant, anti-aging, immunomodulatory, antidepressant, memory-enhancing, anti-tumor, and anti-fatigue properties. Currently, there are no research reports on the use of Morinda officinalis volatile oil for hyperlipidemia.

[0018] Coptis chinensis is the dried rhizome of three plants: Coptis chinensis Franch., Coptis deltoidea CYCheng et Hsiao, and Coptis teeta Wall., belonging to the Ranunculaceae family. It is bitter and cold in nature, and enters the heart, spleen, stomach, liver, gallbladder, and large intestine meridians. It has the effects of clearing heat and drying dampness, purging fire and detoxifying. It is used for damp-heat fullness, vomiting and acid regurgitation, diarrhea, jaundice, high fever with delirium, excessive heart fire, restlessness and insomnia, palpitations, hematemesis due to blood heat, red eyes, toothache, diabetes, carbuncles and boils; externally, it is used to treat eczema, damp sores, and ear discharge. Coptis chinensis contains alkaloids, flavonoids, lignans, organic acids, and volatile oils, among other active ingredients. The volatile oil of Coptis chinensis mainly includes monoterpenes, sesquiterpenes, and their oxygenated derivatives, which have pharmacological effects such as antibacterial, anti-inflammatory, antioxidant, antitumor, and improvement of cardiovascular function.

[0019] Costus root: The dried root of Aucklandia lappa Decne., a plant in the Asteraceae family; pungent, bitter, and warm in nature, it enters the spleen, stomach, large intestine, triple burner, and gallbladder meridians; it has the effects of promoting qi circulation and relieving pain, strengthening the spleen and promoting digestion, and is used for symptoms such as chest and rib pain, abdominal distension and pain, tenesmus after diarrhea, indigestion, and loss of appetite; the volatile oil of costus root contains terpenoids, aromatic compounds, etc., and has pharmacological effects such as regulating gastrointestinal function, anti-inflammatory, antioxidant, cardiovascular protection, anti-tumor, anti-anxiety, and sedative effects.

[0020] (III) Beneficial Effects

[0021] The traditional Chinese medicine compound essential oil provided by this invention, composed of Morinda officinalis essential oil, Coptis chinensis essential oil, and Aucklandia lappa essential oil, has great application potential in the treatment or prevention of hyperlipidemia. Specifically, the compound essential oil of this invention can significantly reduce the weight gain trend in hyperlipidemic mouse models, reduce mouse weight, effectively reduce the levels of triglycerides, cholesterol, and LDL in the serum and liver of hyperlipidemic mouse models, increase the level of HDL, significantly improve the hyperlipidemic symptoms of model mice, and achieve the purpose of regulating lipid metabolism; at the same time, it can inhibit hepatic steatosis and reduce the diameter of adipocytes; furthermore, the compound essential oil of this invention may achieve its therapeutic effect on hyperlipidemic mice by upregulating lipid oxidation and decomposition-related genes ATGL, HSL, PPAR-α, and CPT-1, and inhibiting PPAR-γ, SCD-1, FAS, and Cidea lipid synthesis genes. Attached Figure Description

[0022] Figure 1 The effects of different formulations of compound essential oils on body weight (A) and serum TC (B) and TG (C) levels in hyperlipidemic model mice were investigated. Note: In (A), *P<0.05, **P<0.01; in (B) and (C), *P<0.05, **P<0.01 compared with the HFD group, and *P<0.05, **P<0.01 compared with the F1 group, # P<0.05.

[0023] Figure 2 The values ​​represent the changes in body weight of mice in each group (A), and the serum TC (B), TG (C), HDL (D), LDL (G) levels and liver TC (E) and TG (F) levels in different groups of mice. Note: ns P>0.05, *P<0.05, **P<0.01.

[0024] Figure 3 HE staining and Oil Red staining images of liver and fat in mice from each group.

[0025] Figure 4 The results show the expression levels of genes related to liver lipid metabolism in mice in each group. Note: ns P>0.05, *P<0.05, **P<0.01. Detailed Implementation

[0026] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions of the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0027] Example 1

[0028] A compound essential oil of traditional Chinese medicine, wherein the compound essential oil of traditional Chinese medicine is composed of the following parts by volume of essential oils of traditional Chinese medicine plants: 0.6 parts of Morinda officinalis essential oil, 1 part of Coptis chinensis essential oil, and 1 part of Aucklandia lappa essential oil.

[0029] Morinda officinalis essential oil, Coptis chinensis essential oil, and Costus root essential oil are extracted from the Chinese herbal medicines Morinda officinalis, Coptis chinensis, and Costus root using supercritical carbon dioxide extraction, respectively, maintaining a purity of over 99%.

[0030] The aforementioned compound essential oils from traditional Chinese medicine are used to prepare products for the prevention and / or improvement and / or treatment of hyperlipidemia. These products are for aromatherapy, specifically formulated by weighing Morinda officinalis essential oil, Coptis chinensis essential oil, and Aucklandia lappa essential oil according to the aforementioned volume proportions, mixing them thoroughly, and then adding medically acceptable excipients to create a topical dosage form for aromatherapy. The effective content of the compound essential oils in the product is above 20%.

[0031] Example 2

[0032] The difference between this embodiment and Embodiment 1 is that the compound essential oil of traditional Chinese medicine is composed of the following volume parts of traditional Chinese medicine plant essential oils: 0.1 parts of Morinda officinalis essential oil, 0.5 parts of Coptis chinensis essential oil, and 0.5 parts of Aucklandia lappa essential oil.

[0033] Example 3

[0034] The difference between this embodiment and Embodiment 1 is that the compound essential oil of traditional Chinese medicine is composed of the following volume parts of essential oils of traditional Chinese medicine plants: 2 parts of Morinda officinalis essential oil, 3 parts of Coptis chinensis essential oil, and 3 parts of Aucklandia lappa essential oil.

[0035] Example 4

[0036] The difference between this embodiment and Embodiment 1 is that the compound Chinese medicine essential oil is composed of the following volume parts of Chinese herbal plant essential oils: 1.5 parts of Morinda officinalis essential oil, 2.8 parts of Coptis chinensis essential oil, and 2.8 parts of Aucklandia lappa essential oil.

[0037] Example 5

[0038] The difference between this embodiment and Embodiment 1 is that the compound Chinese medicine essential oil is composed of the following volume parts of Chinese herbal plant essential oils: 0.3 parts of Morinda officinalis essential oil, 0.8 parts of Coptis chinensis essential oil, and 0.8 parts of Aucklandia lappa essential oil.

[0039] Example 6

[0040] The difference between this embodiment and Embodiment 1 is that the compound essential oil of traditional Chinese medicine is composed of the following volume parts of traditional Chinese medicine plant essential oils: 1.2 parts of Morinda officinalis essential oil, 2 parts of Coptis chinensis essential oil, and 2 parts of Aucklandia lappa essential oil.

[0041] Example 7

[0042] The difference between this embodiment and Embodiment 1 is that the compound Chinese medicine essential oil is composed of the following volume parts of Chinese herbal plant essential oils: 0.8 parts of Morinda officinalis essential oil, 1.2 parts of Coptis chinensis essential oil, and 1.5 parts of Aucklandia lappa essential oil.

[0043] Experimental Example 1

[0044] This invention relates to a compound essential oil of traditional Chinese medicine, which is obtained by rationally combining different Chinese herbal plants based on their characteristics and pharmacological effects. The effects of compound essential oils composed of multiple different Chinese herbal plants on a mouse model of hyperlipidemia were studied. Due to the large amount of experimental data, a screening experiment with different formulations is provided to illustrate the advantages of the compound Chinese medicine of this invention.

[0045] 1. Laboratory animals

[0046] Seven-week-old, standard strain C57BL / 6J mice, weighing (20±1) g, were housed in a room with controlled temperature and humidity, with free access to food and water, and a 12-hour light / dark cycle. They were fed standard laboratory feed (product number 1010001, Jiangsu Xiehe Pharmaceutical Biotechnology Co., Ltd.) and were put into the experiment after one week of acclimatization.

[0047] 2 Experimental drugs

[0048] Compound Essential Oil 1: 0.6 parts Morinda officinalis essential oil, 1 part Coptis chinensis essential oil, 1 part Aucklandia lappa essential oil

[0049] Compound Essential Oil 2: 0.3 parts Morinda officinalis essential oil, 1 part Coptis chinensis essential oil, 1 part Aucklandia lappa essential oil

[0050] Compound essential oil 3: 1 part Coptis chinensis essential oil, 1 part Aucklandia lappa essential oil

[0051] Compound Essential Oil 4: Epimedium essential oil 0.6 parts, Coptis chinensis essential oil 1 part, Aucklandia lappa essential oil 1 part

[0052] Compound Essential Oil 5: Morinda officinalis essential oil 0.6 parts, Phellodendron chinense essential oil 1 part, Citrus reticulata essential oil 1 part

[0053] The above single essential oils were obtained from Morinda officinalis, Coptis chinensis, Aucklandia lappa, Epimedium brevicornu, Phellodendron chinense, and Citrus reticulata peel using supercritical carbon dioxide extraction, with a purity of over 99%. The single essential oils were mixed evenly according to the above volume proportions to obtain compound essential oils 1-5, which were then refrigerated for later use.

[0054] 3. Animal modeling and grouping

[0055] Forty-two C57 / Bl6J mice, after one week of acclimatization, were randomly assigned to cages of six. The mice were then randomly divided into seven groups: a control diet group (NC group), a high-fat diet group (HFD group), and groups receiving a high-fat diet plus compound essential oil 1 (Experimental Group 1, F1), 2 (Experimental Group 2, F2), 3 (Experimental Group 3, F3), 4 (Experimental Group 4, F4), and 5 (Experimental Group 5, F5). The essential oil groups received 10 μL of the corresponding compound essential oil per mouse daily, applied to both sides of the nose; the HFD group received saline instead. Both the HFD and essential oil groups continued to be fed the high-fat diet (D12492, Research diets) with free access to food and water for eight weeks.

[0056] 4 Observation Indicators

[0057] During the experiment, the weight gain of mice in each group was recorded, the weight growth rate of each group was calculated, blood was collected by ocular blood collection, and the total cholesterol (TC) and triglycerides (TG) in the blood were measured.

[0058] Weight gain rate = Final weight / Initial weight × 100%

[0059] 5 Statistical Methods

[0060] The quantitative data were processed and statistically analyzed using Prism software, and expressed as mean ± standard error (x ± sem). One-way ANOVA was used to analyze the significance between groups. P < 0.05 was considered statistically significant, and P < 0.01 indicated a statistically significant difference.

[0061] 6 Results

[0062] 6.1 Effect on body weight of hyperlipidemic mouse model

[0063] like Figure 1 As shown in Figure A, compared with the NC group, the weight gain rate of mice in the HFD group was significantly increased (P < 0.01), indicating that the obesity and hyperlipidemia model was successfully established. Compared with the HFD group, the weight gain rate of mice in groups F1-F5 was significantly lower than that of the HFD group (P < 0.01). Among them, the weight gain rate of mice in group F1 was significantly lower than that of mice in groups F2-F5 (P < 0.05).

[0064] 6.2 Effects on lipid parameters in a hyperlipidemic mouse model

[0065] The results of TC and TG levels in the blood of mice in each group at the end of the experiment are as follows: Figure 1As shown in B and C. Compared with the NC group, the TC and TG levels in the HFD group mice were significantly increased (P<0.01), further confirming the successful establishment of the obesity and hyperlipidemia model. Compared with the HFD group, the TC and TG levels in the F1-F5 groups were decreased to varying degrees. The TC levels in the F1-F3 and F5 groups were significantly lower than those in the HFD group (P<0.05 or P<0.01), and the TG levels in the F1-F2 and F5 groups were significantly lower than those in the HFD group (P<0.05 or P<0.01). The TG level in the F3 group was slightly lower than that in the HFD group, but there was no significant difference (P>0.05). The TC and TG levels in the F4 group were slightly lower than those in the HFD group, but there was no significant difference (P>0.05). Among them, the TC level in the F1 group was significantly lower than that in the F2-F5 groups (P<0.05).

[0066] 7 Conclusions

[0067] This experiment successfully constructed a hyperlipidemic mouse model and explored the effects of different formulated essential oils on the model. First, the results of groups F1-F3 showed that the compound essential oil with the addition of Morinda officinalis essential oil to Coptis chinensis and Aucklandia lappa essential oils significantly reduced the body weight and serum TC and TG levels in the hyperlipidemic mouse model. Furthermore, the increased content of Morinda officinalis essential oil resulted in a more significant effect. Secondly, the results of groups F1 and F3-F5 indicated that the Morinda officinalis, Coptis chinensis, and Aucklandia lappa essential oils provided in this invention exhibit a synergistic effect. Replacing any one of these components failed to achieve the desired effect of reducing body weight and improving lipid profiles in hyperlipidemic mice; all components are indispensable.

[0068] Experimental Example 2

[0069] The following animal experimental data are provided to further illustrate the application prospects of the compound essential oil of traditional Chinese medicine in the prevention and treatment of hyperlipidemia.

[0070] 1. Laboratory animals

[0071] Seven-week-old, standard strain C57 / Bl6J mice, weighing (20±1) g, were housed in a room with controlled temperature and humidity, with free access to food and water, and a 12-hour light / dark cycle. They were fed standard laboratory feed (product number 1010001, Jiangsu Xiehe Pharmaceutical Biotechnology Co., Ltd.) and were put into the experiment after one week of acclimatization.

[0072] 2. Relapse-prone essential oils

[0073] Mix 0.6 parts Morinda officinalis essential oil with 1 part Coptis chinensis essential oil and 1 part Aucklandia lappa essential oil according to the above volume proportions, and refrigerate for later use. Store the essential oil solution in a well-sealed essential oil bottle and refrigerate for later use. All the above essential oils were obtained from Morinda officinalis, Coptis chinensis, and Aucklandia lappa using carbon dioxide extraction, and their purity is all above 99%.

[0074] 3. Animal grouping and treatment

[0075] Twenty C57 / Bl6J mice, after one week of acclimatization, were randomly assigned to cages of five. The mice were then randomly divided into four groups: a control diet group (NC group), a high-fat diet group (HFD group), a high-fat diet plus low-dose compound essential oil group (BHM-L group, low-dose, 5 μL / mouse), and a high-fat diet plus high-dose compound essential oil group (BHM-H group, high-dose, 10 μL / mouse). The essential oil group received the medication daily via inhalation, applied to both sides of the nose once a day; the HFD group received saline instead. The HFD group, essential oil group, and positive control group continued to be fed the high-fat diet (D12492, Research diets) with free access to food and water for 11 weeks.

[0076] Two days before the end of the experiment, fresh feces from each mouse were collected and immediately frozen at -80°C. After the experiment, the mice were euthanized by cervical dislocation, and blood was collected and centrifuged to obtain serum. Liver and epididymal fat were also collected and immediately placed in liquid nitrogen at -80°C for further analysis. The liver was weighed and divided into three portions the size of soybeans for subsequent QPCR to verify the expression of lipid metabolism-related genes. Some fat and liver were used for HE sectioning to observe pathological changes.

[0077] 4 detection indicators

[0078] 4.1 Mouse body weight and liver weight detection

[0079] During the experiment, the food intake and body weight of mice in each group were observed and recorded. After the experiment, the mice were sacrificed, and the liver weight was taken to calculate the liver index.

[0080] 4.2 Serum and liver lipid tests

[0081] The levels of TC, TG, HDL, and LDL in the serum and liver of mice in each group were measured.

[0082] 4.3 Pathological examination of mouse liver and adipose tissue

[0083] Mouse liver and epididymal tissues were fixed in formalin for 24 hours, then dehydrated, embedded, and stained, and finally imaged under a microscope.

[0084] 4.4 Detection of expression levels of genes related to liver lipid metabolism in mice

[0085] Liver tissues stored at -80 ℃ were removed, and 20 mg of tissue was weighed out. Total RNA was extracted and reverse transcribed into cDNA using a reverse transcription kit. The cDNA was then used as a template for quantitative real-time PCR amplification. GAPDH was used as an internal control. -ΔΔCT The mNRA expression of related genes was calculated using a method.

[0086] Primer sequences are as follows

[0087] Gene upstream primer Downstream primer Ppara TTTCACAAGTGCCTGTCTGTCG TCTTCAGGTAGGCTTCGTGGAT Cyp7a1 GCTAAGGAGGACTTCACTCTACACC TGGTCTTTGCTTTCCCACTTTC Cpt1a GCCTCTATGTGGTGTCCAAGTATC CACCATAGCCGTCATCAGCAA SCD-1 GTTAGCACCTTCTTGCGATACACT GTGAAGTTGATGTGCCAGCG FAS CTGCCTCTGGTGCTTGCT ACCCGCCTCCTCAGCTTT PPAR-γ GACCACTCGCATTCCTTTGA CCACAGACTCGGCACTCAAT GAPDH CCTCGTCCCGTAGACAAAATG TGAGGTCAATGAAGGGGTCGT AHDH5 GGTTAAGTCTAGTGCAGCGTTTG GTACTCTGTCACCGTGTCATCTT ATGL CCAACATTATTGAGGTGTCCAAGG AGTGGGATATGATGACGTTCTCTC HSL GGAAGGACAGGACAGCAAGGTA GAGGTAGGGCTCGTGGGATTTA

[0088] Note: AHDH5, autohydrolase domain 5; ATGL, triglyceride lipase; HSL, hormone-sensitive lipase; PPAR-α, peroxisome proliferator-activated receptor α; PPAR-γ, peroxisome proliferator-activated receptor gama; CYP7A1, cholesterol 7-α hydroxylase; CPT-1, carnitine palmitoyltransferase 1; FAS, fatty acid synthase; SCD-1, stearoyl-CoA desaturase-1; GAPDH, 3-phosphate dehydrogenase.

[0089] 5 Statistical Methods

[0090] The quantitative data were processed and statistically analyzed using Prism software, and expressed as mean ± standard error (x ± sem). One-way ANOVA was used to analyze the significance between groups. P < 0.05 was considered statistically significant, and P < 0.01 indicated a statistically significant difference. For quantitative experiments, unless otherwise specified, three replicates were performed, and the results were averaged.

[0091] 6 Results

[0092] 6.1 Effects of the compound essential oil of traditional Chinese medicine on the body weight of mice with hyperlipidemia.

[0093] like Figure 2 As shown in Figure A, during the experiment, the body weight of mice in the HFD group was significantly increased compared with that in the NC group (P<0.001); compared with that in the HFD group, the body weight of mice in both the BHM-H and BHM-L groups was significantly decreased (P<0.05).

[0094] 6.2 Effects of the compound essential oil of traditional Chinese medicine on serum and liver biochemical indicators in hyperlipidemic mouse model mice

[0095] like Figure 2As shown in Figure 1, compared with the NC group, the HFD group showed significantly increased levels of TC and TG in serum and liver (P<0.01), significantly increased serum LDL (P<0.01), and significantly decreased HDL (P<0.01), indicating successful establishment of the hyperlipidemia model. Compared with the HFD group, the BHM-H group showed significantly decreased levels of TC and TG in serum and liver (P<0.01), significantly increased serum HDL (P<0.01), and decreased serum LDL, but the differences were not significant (P>0.05); the BHM-L group showed significantly decreased levels of TC and TG in serum and liver (P<0.05), increased serum HDL, and decreased serum LDL, but the differences were not significant (P>0.05).

[0096] 6.3 Effects of the compound essential oil of traditional Chinese medicine on the pathology of liver and adipose tissue in hyperlipidemic mouse models

[0097] The results are as follows Figure 3 As shown, after HE and Oil Red staining of mouse liver and fat, it was found that compared with the NC group, the HFD group showed a significant increase in the degree of steatosis in the liver, obvious vacuolation, and increased fat droplet diameter; compared with the HFD group, the BHM-H and BHM-L groups showed a significant decrease in steatosis in the liver and a significant decrease in fat droplet diameter.

[0098] 6.4 Effects of the compound essential oil of traditional Chinese medicine on lipid metabolism-related factors in hyperlipidemic mouse model

[0099] like Figure 4 As shown, compared with the NC group, the lipolysis genes AHDH5, ATGL, HSL and lipid oxidation genes CPT-1 and CYP7A1 in the liver of HFD group mice were significantly downregulated (P<0.05), while the lipid synthesis genes PPAR-γ, SCD-1, and FAS were significantly upregulated (P<0.05 or P<0.01). Compared with the HFD group, the lipid oxidation-related genes ATGL, HSL, PPAR-α, and CPT-1 in BHM-H and BHM-L group mice were significantly upregulated (P<0.01), while the lipid synthesis genes PPAR-γ, SCD-1, FAS, and Cidea showed a significant downregulation trend.

[0100] 7 Conclusions

[0101] The above results further indicate that the compound essential oil of traditional Chinese medicine in this invention can significantly reduce the weight gain trend of hyperlipidemic mouse models, reduce the content of TC, TG, and LDL in the serum and liver of hyperlipidemic mouse models, increase the content of HDL, improve the pathological condition of liver and adipose tissue in hyperlipidemic mouse models, reduce fatty degeneration in the liver, and reduce the diameter of fat droplets. The compound essential oil of traditional Chinese medicine in this invention may achieve its therapeutic effect on hyperlipidemic mice by upregulating the lipid oxidation and decomposition related genes ATGL, HSL, PPAR-α, and CPT-1, and inhibiting the lipid synthesis genes PPAR-γ, SCD-1, FAS, and Cidea.

[0102] The above embodiments are only used to illustrate the technical solutions of the present invention, and are not intended to limit it. Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some of the technical features. Such modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A compound essential oil made from traditional Chinese medicine, characterized in that, The herbal compound essential oil is composed of the following volume parts of herbal plant essential oils: 0.1-2 parts of Morinda officinalis essential oil, 0.5-3 parts of Coptis chinensis essential oil, and 0.5-3 parts of Aucklandia lappa essential oil.

2. The traditional Chinese medicine compound essential oil according to claim 1, characterized in that, The herbal compound essential oil is composed of the following volume parts of herbal plant essential oils: Morinda officinalis essential oil 0.3-1.2 parts, Coptis chinensis essential oil 0.8-2 parts, and Aucklandia lappa essential oil 0.8-2 parts.

3. The traditional Chinese medicine compound essential oil according to claim 1, characterized in that, The herbal compound essential oil is composed of the following volume parts of herbal plant essential oils: 0.6 parts Morinda officinalis essential oil, 1 part Coptis chinensis essential oil, and 1 part Aucklandia lappa essential oil.

4. A traditional Chinese medicine compound essential oil according to any one of claims 1 to 3, characterized in that, Morinda officinalis essential oil, Coptis chinensis essential oil, and Costus root essential oil are extracted from the Chinese herbal medicines Morinda officinalis, Coptis chinensis, and Costus root using supercritical carbon dioxide extraction, respectively, maintaining a purity of over 99%.

5. The use of the traditional Chinese medicine compound essential oil according to any one of claims 1 to 3 in the preparation of products for the prevention and / or improvement and / or treatment of hyperlipidemia, characterized in that, The product is for aromatherapy. Specifically, it is made by weighing Morinda officinalis essential oil, Coptis chinensis essential oil and Aucklandia lappa essential oil according to the above volume proportions, mixing them evenly, adding medically acceptable excipients, and preparing a topical dosage form for aromatherapy.

6. The product for preventing and / or improving and / or treating hyperlipidemia according to claim 5, characterized in that, The effective content of the herbal relapse-prevention essential oil is over 20%.

Citation Information

Patent Citations

  • Compound essential oil capable of reducing weight and preparation method of compound essential oil

    CN109602645A

  • Application of Xianglian product or combination of Xianglian product and antibiotics in anti-helicobacter pylori drugs

    CN113144015A

  • Aucklandia-coptis pill, extract thereof, pharmaceutical composition and new application of aucklandia-coptis pill product

    CN113730464A